Review





Similar Products

alnuctamab bms-986349; cc-93269  (Celgene)
90
Celgene alnuctamab bms-986349; cc-93269
Approved and clinical late-stage antibodies for multiple myeloma
Alnuctamab Bms 986349; Cc 93269, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alnuctamab bms-986349; cc-93269/product/Celgene
Average 90 stars, based on 1 article reviews
alnuctamab bms-986349; cc-93269 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cc-93269 (em801)  (Celgene)
90
Celgene cc-93269 (em801)
Clinical-stage BsAbs for cancer indications.
Cc 93269 (Em801), supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cc-93269 (em801)/product/Celgene
Average 90 stars, based on 1 article reviews
cc-93269 (em801) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
alnuctamab cc-93269  (Bristol Myers)
90
Bristol Myers alnuctamab cc-93269
Selected active trials of additional CD3 x BCMA targeting bispecific antibodies in multiple myeloma (MM).
Alnuctamab Cc 93269, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alnuctamab cc-93269/product/Bristol Myers
Average 90 stars, based on 1 article reviews
alnuctamab cc-93269 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
alnuctamab cc-93269  (Celgene)
90
Celgene alnuctamab cc-93269
Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023
Alnuctamab Cc 93269, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alnuctamab cc-93269/product/Celgene
Average 90 stars, based on 1 article reviews
alnuctamab cc-93269 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cc-93269  (Celgene)
90
Celgene cc-93269
Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023
Cc 93269, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cc-93269/product/Celgene
Average 90 stars, based on 1 article reviews
cc-93269 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cc-93269 antibody  (Celgene)
90
Celgene cc-93269 antibody
Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023
Cc 93269 Antibody, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cc-93269 antibody/product/Celgene
Average 90 stars, based on 1 article reviews
cc-93269 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cc-93269/em801  (Celgene)
90
Celgene cc-93269/em801
Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023
Cc 93269/Em801, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cc-93269/em801/product/Celgene
Average 90 stars, based on 1 article reviews
cc-93269/em801 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cc-93269  (Bristol Myers)
90
Bristol Myers cc-93269
Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023
Cc 93269, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cc-93269/product/Bristol Myers
Average 90 stars, based on 1 article reviews
cc-93269 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Approved and clinical late-stage antibodies for multiple myeloma

Journal: Antibody Therapeutics

Article Title: Structure and function of therapeutic antibodies approved by the US FDA in 2023

doi: 10.1093/abt/tbae007

Figure Lengend Snippet: Approved and clinical late-stage antibodies for multiple myeloma

Article Snippet: Alnuctamab (BMS-986349; CC-93269) , Celgene , BCMA × CD3ε , Phase 3 (NCT06232707; not yet recruiting) , N = 26 (at 30 mg target dose) ORR: 65% CR: 19% MDOR: 33.6 mo (all doses and ROAs) , CRS: 76% all grades , Asymmetric trivalent, bispecific (2:1) design , [ , ] .

Techniques:

Clinical-stage BsAbs for cancer indications.

Journal: Frontiers in Immunology

Article Title: Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

doi: 10.3389/fimmu.2023.1291836

Figure Lengend Snippet: Clinical-stage BsAbs for cancer indications.

Article Snippet: , CC-93269 (EM801) , Fab3CrossMab*J , MM , Phase 1 , Celgene , NCT03486067 , .

Techniques: Amplification

Selected active trials of additional CD3 x BCMA targeting bispecific antibodies in multiple myeloma (MM).

Journal: International Journal of Molecular Sciences

Article Title: Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

doi: 10.3390/ijms242115674

Figure Lengend Snippet: Selected active trials of additional CD3 x BCMA targeting bispecific antibodies in multiple myeloma (MM).

Article Snippet: Alnuctamab (CC-93269): a 2 + 1 T-cell engager from Bristol Myers Squibb with two arms binding to BCMA and one arm to CD3ε [ ].

Techniques: Drug discovery, Activity Assay, Injection

Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023

Journal: Journal of Hematology & Oncology

Article Title: Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies

doi: 10.1186/s13045-023-01482-w

Figure Lengend Snippet: Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023

Article Snippet: Alnuctamab (CC-93269) , Hz 2 + 1 VH−VL± CrossMab , BCMA/CD3 , MM , NCT03486067 , 1 , Celgene (BMS).

Techniques: Clinical Proteomics